Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manish Patel

Urology Charlotte, NC Medical Doctor

NPI 1558655936 CMS profile 606936

1225 Harding Pl, Ste 3100, Charlotte, NC 28204

Open in the dashboard

General payments

$83,613

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manish Patel of Charlotte, NC is reported in the CMS Open Payments database as having received $83,613 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $419 8
2024 General $653 10
2023 General $28,162 16
2022 General $779 8
2021 General $44,870 21
2020 General $3,599 7
2019 General $5,131 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manish Patel
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Manish Patel were reported at $419. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Manish Patel Urology median Middle half National median
2019 $5,131 $480 $147–$1,201 $163
2020 $3,599 $246 $87–$645 $114
2021 $44,870 $358 $111–$1,000 $132
2022 $779 $476 $143–$1,263 $149
2023 $28,162 $560 $168–$1,461 $160
2024 $653 $563 $170–$1,464 $164
2025 $419 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $76,521 48 payments
  2. Axonics Modulation Technologies, Inc. $3,261 6 payments
  3. Boston Scientific Corporation $2,086 34 payments
  4. NeoTract Inc. $519 1 payment
  5. Lumenis, Inc $262 1 payment
  6. Olympus America Inc. $205 2 payments
  7. Urogen Pharma, Inc. $171 1 payment
  8. Agiliti Surgical, Inc. $143 2 payments
  9. Ambu Inc. $120 1 payment
  10. Tempus AI, Inc $118 1 payment
  11. Other $206 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $48,207 9 payments
  2. Education $21,606 7 payments
  3. Travel and Lodging $5,520 25 payments
  4. Food and Beverage $4,218 57 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,262 3 payments
  6. Consulting Fee $800 2 payments
Products named General payments · program years 2019–2025
  1. Altis Women's Health $71,590 23 payments
  2. ALTIS Female Incontinence $3,258 16 payments
  3. Axonics r-SNM System $3,000 2 payments
  4. AXIS $1,064 6 payments
  5. LithoVue LithoVue_URO $892 14 payments
  6. UROLIFT $519 1 payment
  7. Titan $400 1 payment
  8. General - Kidney Stone Disease $191 6 payments
  9. JELMYTO $171 1 payment
  10. LITHOVUE Lithovue $167 2 payments
  11. Other $1,842 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

667

Median for Urology: 1,053

Drug cost

$11,018

Median for Urology: $101,464

Branded share of claims

25.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trospium Chloride Generic 56 $2,799
Potassium Citrate Er Potassium Citrate Brand 15 $2,481
Tamsulosin Hcl Generic 145 $1,269
Ampicillin Trihydrate Generic 42 $742
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 16 $497
Ondansetron Odt Ondansetron Brand 62 $490
Cefdinir Generic 20 $442
Cephalexin Generic 51 $433
Finasteride Generic 34 $390
Cefuroxime Cefuroxime Axetil Brand 16 $248

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$66,128

Medicare's payments for the services billed

Medicare patients

200

Average age 71

Services billed

644

76 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Chronic kidney disease 41%
Ischemic heart disease 32%
Diabetes 31%
Depression 27%
Cancer 26%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record